Bulging order book for bioconjugates lifts WuXi XDC profits
The provider of outsourced pharmaceutical services has delivered unexpectedly strong half-year earnings and has launched its first overseas production hub Key Takeaways: WuXi XDC began operations in August at a…
BRIEF: WuXi XDC profit jumps on rising revenue, improving margins
Pharmaceutical contract services provider WuXi XDC Cayman Inc. (2268.HK) said on Wednesday it expects to report its annual revenue rose 45% in 2025, as its gross profit surged over 70%…
3SBio gears up for drugs battle with $400 million equity move
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio…
WuXi AppTec frees up money for Middle East push
The drugs services giant has stepped up sales of non-core Chinese assets to concentrate on its international expansion, with plans for a base in Saudi Arabia Key Takeaways: The company…
BRIEF: WuXi XDC to raise $348 million via share placements at 4% discount
Contract drug services provider WuXi XDC Cayman Inc. (2268.HK) on Wednesday announced two share placements to raise a combined HK$2.71 billion ($348 million) in new funds. The company plans to…
Rising profit at WuXi Biologics underscores drug sector rebound
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expects…
Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
Recent Articles
WuXi AppTec frees up money for Middle East push
2359.HK
603259.SHG
Fortune smiles again on WuXi AppTec with profit surge
2359.HK
603259.SHG
